Syngene International Limited — Important, 23-01-2025: Financial Result Updates

**Syngene International Limited Financial Results Summary**

Syngene International reported consolidated revenue of ₹9,620 crore for the quarter, signifying a year-over-year growth of 9.23%. The primary drivers behind this increase include expanding contract research services and enhanced demand in the biopharmaceutical sector.

Net profit for the quarter stands at ₹1,311 crore, up from ₹1,061 crore in the previous year, representing a growth of 23.5%. This improvement in profitability was bolstered by cost-effective operations and efficient supply chain management, alongside the absorption of fixed costs over a larger revenue base. Earnings per share (EPS) increased to ₹3.27 from ₹2.64.

Operational costs rose by 5.36%, primarily due to fluctuations in raw material prices and increased staffing costs to support business growth. However, the company successfully managed its cost structure, reflecting solid operational efficiency.

In terms of balance sheet health, total assets increased to ₹42,000 crore, with a debt-to-equity ratio remaining stable, indicating sound financial leverage. Cash flow from operating activities improved, providing further liquidity for future investments.

Strategically, Syngene is focusing on enhancing its manufacturing capabilities while driving innovation in research services, which is likely to continue attracting new clients. The overall market sentiment appears positive, given the ongoing demand for biotechnology services.

For investors, the current performance and strategic outlook suggest a **buy** for those looking to capitalize on the firm’s growth trajectory in the expanding biopharma sector.